Search Results - "Nilubol, Naris"

Editorial: Molecular Mechanisms in Cancer Endocrinology With Clinical Implications by Nilubol, Naris

Get full text

The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment by Laha, Dipranjan, Grant, Robert, Mishra, Prachi, Nilubol, Naris

“…The tumor microenvironment (TME) is an intricate system within solid neoplasms. In this review, we aim to provide an updated insight into the TME with a focus…”
Get full text

New Therapies for Advanced Thyroid Cancer by Laha, Diprajan, Nilubol, Naris, Boufraqech, Myriem

“…Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the…”
Get full text

Current Status and Future Targeted Therapy in Adrenocortical Cancer by Alyateem, George, Nilubol, Naris

“…Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. The current treatment standards include complete surgical resection for localized…”
Get full text

Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases by Kotian, Shweta, Zhang, Lisa, Boufraqech, Myriem, Gaskins, Kelli, Gara, Sudheer Kumar, Quezado, Martha, Nilubol, Naris, Kebebew, Electron

“…There is currently no standard therapy for anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC), which account for two-thirds of…”
Get full text

Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma by Satoh, Kei, Zhang, Lisa, Zhang, Yaqin, Chelluri, Raju, Boufraqech, Myriem, Nilubol, Naris, Patel, Dhaval, Shen, Min, Kebebew, Electron

“…Adrenocortical carcinoma (ACC) is a rare and aggressive cancer, and no current effective therapy is available for locally advanced and metastatic ACC. Drug…”
Get full text

Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure by Libutti, Steven K, Tamarkin, Lawrence, Nilubol, Naris

“…Although a number of new systemic therapeutic options in patients with advanced solid cancers have emerged due to the improved knowledge of molecular…”
Get full text

Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers by Boufraqech, Myriem, Zhang, Lisa, Nilubol, Naris, Sadowski, Samira M, Kotian, Shweta, Quezado, Martha, Kebebew, Electron

“…Epithelial-to-mesenchymal transition (EMT) is important in cancer progression and metastasis. We and others have previously reported that lysyl oxidase (LOX)…”
Get full text

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors by Patel, Dhaval, MD, Boufraqech, Myriem, PhD, Jain, Meenu, PhD, Zhang, Lisa, PhD, He, Mei, MD, Gesuwan, Krisana, CRNP, Gulati, Neelam, BS, Nilubol, Naris, MD, Fojo, Tito, MD, PhD, Kebebew, Electron, MD

“…Background Nonfunctioning adrenal incidentalomas are common and many patients undergo adrenalectomy to exclude adrenocortical carcinoma (ACC). Recent studies…”
Get full text

ASO Author Reflections: Predicting Postoperative Resolution of Hypertension in Primary Hyperaldosteronism by Chatani, Praveen D., Dominguez, Dana A., Nilubol, Naris

Get full text

Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms by Patel, Dhaval, Thompson, Matthew D, Manna, Soumen K, Krausz, Kristopher W, Zhang, Lisa, Nilubol, Naris, Gonzalez, Frank J, Kebebew, Electron

“…Adrenal incidentalomas must be differentiated from adrenocortical cancer (ACC). Currently, size, growth, and imaging characteristics determine the potential…”
Get full text

Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis by Keutgen, Xavier M., MD, Nilubol, Naris, MD, Kebebew, Electron, MD

“…Background Malignant-functioning pancreatic neuroendocrine tumors (mFpNETs) are rare. Research analyzing the presentation, biological behavior, and patient…”
Get full text

Hyperparathyroidism-jaw tumor syndrome: Results of operative management by Mehta, Amit, BA, Patel, Dhaval, MD, BS, Rosenberg, Avi, MD, Boufraqech, Myriem, PhD, Ellis, Ryan J., BS, Nilubol, Naris, MD, Quezado, Martha M., MD, Marx, Stephen J., MD, Simonds, William F., MD, Kebebew, Electron, MD

“…Background Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a rare, autosomal-dominant disease secondary to germline-inactivating mutations of the tumor…”
Get full text

Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors by Keutgen, Xavier M., MD, Nilubol, Naris, MD, Glanville, Joanne, MD, Sadowski, Samira M., MD, Liewehr, David J., MS, Venzon, David J., PhD, Steinberg, Seth M., PhD, Kebebew, Electron, MD

“…Background Nonfunctioning pancreatic neuroendocrine tumors (NFpNET) present with distant metastases in up to 50% of patients. It is unknown whether removal of…”
Get full text

Contralateral Suppression Index Does Not Predict Clinical Cure in Patients Undergoing Surgery for Primary Aldosteronism by Dominguez, Dana A., Chatani, Praveen, Murphy, Ryan, Copeland, Amy R., Chang, Richard, Sadowski, Samira M., Hannah-Shmouni, Fady, Stratakis, Constantine A., Nilubol, Naris

“…Background Adrenal venous sampling (AVS) is recommended before adrenalectomy for patients with primary aldosteronism (PA) over 35 years old. The literature…”
Get full text

SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma by Assadipour, Yasmine, MD, Sadowski, Samira M., MD, Alimchandani, Meghna, MD, Quezado, Martha, MD, Steinberg, Seth M., PhD, Nilubol, Naris, MD, Patel, Dhaval, MD, Prodanov, Tamara, MD, Pacak, Karel, MD, Kebebew, Electron, MD

“…Background A staging/prognostic system has long been desired to better categorize pheochromocytoma/paraganglioma which can be very aggressive in the setting of…”
Get full text

Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome by Aufforth, Rachel D, Ramakant, Pooja, Sadowski, Samira M, Mehta, Amit, Trebska-McGowan, Katarzyna, Nilubol, Naris, Pacak, Karel, Kebebew, Electron

“…Context: Patients with von Hippel-Lindau (VHL) syndrome have a 25–30% chance of developing pheochromocytoma. Although practice guidelines recommend biochemical…”
Get full text

Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery by Nockel, Pavel, El Lakis, Mustapha, Gaitanidis, Apostolos, Merkel, Roxanne, Patel, Dhaval, Nilubol, Naris, Prodanov, Tamara, Pacak, Karel, Kebebew, Electron

“…BACKGROUND:Fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) imaging is recommended in patients with metastatic…”
Get full text

miR30a inhibits LOX expression and anaplastic thyroid cancer progression by Boufraqech, Myriem, Nilubol, Naris, Zhang, Lisa, Gara, Sudheer Kumar, Sadowski, Samira M, Mehta, Amit, He, Mei, Davis, Sean, Dreiling, Jennifer, Copland, John A, Smallridge, Robert C, Quezado, Martha M, Kebebew, Electron

“…Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses…”
Get full text

Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents by Jochmanova, Ivana, Abcede, April Melody T., Guerrero, Ruby Jane S., Malong, Chandy Lou P., Wesley, Robert, Huynh, Thanh, Gonzales, Melissa K., Wolf, Katherine I., Jha, Abhishek, Knue, Marianne, Prodanov, Tamara, Nilubol, Naris, Mercado-Asis, Leilani B., Stratakis, Constantine A., Pacak, Karel

“…Purpose Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare in children with only a few SDHB mutation-related cases. Previous studies on children were…”
Get full text